Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity

International Journal of Neuropsychopharmacology

Volumn 16, Issue 10, 2013, Pages 2273-2284

  Katsidoni, Vicky ^a   Kastellakis, Andreas ^a   Panagis, George ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

9 tetrahydrocannabinol; cannabinoids; intracranial self stimulation; locomotion; SR141716A

Indexed keywords

CANNABINOID 1 RECEPTOR; DRONABINOL; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BEHAVIOR; BRAIN DEPTH STIMULATION; CANNABIS ADDICTION; CONFERENCE PAPER; CONTROLLED STUDY; HYPERACTIVITY; LOCOMOTION; MALE; MOTOR ACTIVITY; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; REWARD;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRONABINOL; ELECTRIC STIMULATION; MALE; MOTOR ACTIVITY; PIPERIDINES; PYRAZOLES; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; REWARD; SELF STIMULATION; TIME FACTORS;

EID: 84885575637     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000709     Document Type: Conference Paper

References (60)

1. Berrendero F, Maldonado R (2002) Involvement of the opioid system in the anxiolytic-like effects induced by delta (9)-Tetrahydrocannabinol. Psychopharmacology (Berl) 163:111-117
2. Braida D, Pozzi M, Cavallini R, Sala M (2001a) Conditioned place preference induced by the cannabinoid agonist CP 55,940: Interaction with the opioid system. Neuroscience 104:923-926
3. Braida D, Pozzi M, Parolaro D, Sala M (2001b) Intracerebral self-Administration of the cannabinoid receptor agonist CP 55,940 in the rat: Interaction with the opioid system. Eur J Pharmacol 413:227-234
4. Braida D, Iosue S, Pegorini S, Sala M (2004) Delta9-Tetrahydrocannabinol- induced conditioned place preference and intracerebroventricular self-Administration in rats. Eur J Pharmacol 506:63-69
5. Braida D, Limonta V, Malabarba L, Zani A, Sala M (2007) 5-HT1A receptors are involved in the anxiolytic effect of delta9-Tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol 555:156-163
6. Carlezon WA Jr., Chartoff EH (2007) Intracranial selfstimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc 2:2987-2995
7. Chaperon F, Soubrie P, Puech AJ, Thiebot MH (1998) Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berl) 135:324-332
8. Cheer JF, Kendall DA, Marsden CA (2000) Cannabinoid receptors and reward in the rat: A conditioned place preference study. Psychopharmacology (Berl) 151:25-30
9. Deneau G, Kaymakcalan S (1971) Physiological and psychological dependence to synthetic ?9-Tetrahydrocannabinol (THC) in rhesus monkeys. Pharmacologist 13:246-248
10. Fokos S, Panagis G (2010) Effects of delta9-Tetrahydrocannabinol on reward and anxiety in rats exposed to chronic unpredictable stress. J Psychopharmacol 24:767-777
11. Gardner EL, Paredes W, Smith D, Donner A, Milling C, Cohen D, Morrison D (1988) Facilitation of brain stimulation reward by delta 9-Tetrahydrocannabinol. Psychopharmacology (Berl) 96:142-144
12. Geyer MA, Paulus MP (1992) Multivariate and nonlinear approaches to characterizing drug effects on the locomotor and investigatory behavior of rats. NIDA Res Monogr 124:203-235
13. Haney M, Comer SD, Ward AS, Foltin RW, Fischman MW (1997) Factors influencing marijuana self-Administration by humans. Behav Pharmacol 8:101-112
14. Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW (2002) Comparison of smoked marijuana and oral delta(9)-Tetrahydrocannabinol in humans. Psychopharmacology (Berl) 164:407-415
15. Hart CL, Haney M, Vosburg SK, Comer SD, Foltin RW (2005) Reinforcing effects of oral delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology (Berl) 181:237-243
16. Hutcheson DM, Tzavara ET, Smadja C, Valjent E, Roques BP, Hanoune J, Maldonado R (1998) Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-Tetrahydrocannabinol. Br J Pharmacol 125:1567-1577
17. Jarbe TU, Andrzejewski ME, DiPatrizio NV (2002) Interactions between the CB1 receptor agonist delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: Open-fi eld revisited. Pharmacol Biochem Behav 73:911-919
18. Justinova Z, Tanda G, Redhi GH, Goldberg SR (2003) Self-Administration of delta9-Tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl) 169:135-140
19. Justinova Z, Goldberg SR, Heishman SJ, Tanda G (2005) Self-Administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav 81:285-299
20. Justinova Z, Munzar P, Panlilio LV, Yasar S, Redhi GH, Tanda G, Goldberg SR (2008) Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. Neuropsychopharmacology 33:2870-2877
21. Katsidoni V, Apazoglou K, Panagis G (2011) Role of serotonin 5-HT2A and 5-HT2C receptors on brain stimulation reward and the reward-facilitating effect of cocaine. Psychopharmacology (Berl) 213:337-354
22. Le Foll B, Wiggins M, Goldberg SR (2006) Nicotine preexposure does not potentiate the locomotor or rewarding effects of delta-9-Tetrahydrocannabinol in rats. Behav Pharmacol 17:195-199
23. Lepore M, Vorel SR, Lowinson J, Gardner EL (1995) Conditioned place preference induced by delta 9-Tetrahydrocannabinol: Comparison with cocaine, morphine, and food reward. Life Sci 56:2073-2080
24. Lepore M, Liu X, Savage V, Matalon D, Gardner EL (1996) Genetic differences in delta 9-Tetrahydrocannabinolinduced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains. Life Sci 58:PL365-PL372
25. McGregor IS, Issakidis CN, Prior G (1996) Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacol Biochem Behav 53:657-664
26. McMahon LR, Koek W (2007) Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. Eur J Pharmacol 569:70-76
27. Maldonado R (2002) Study of cannabinoid dependence in animals. Pharmacol Ther 95:153-164
28. Mallet PE, Beninger RJ (1998) Delta9-Tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance. Life Sci 62:2431-2439
29. Margulies JE, Hammer RP Jr. (1991) Delta 9-Tetrahydrocannabinol alters cerebral metabolism in a biphasic, dose-dependent manner in rat brain. Eur J Pharmacol 202:373-378
30. Martellotta MC, Cossu G, Fattore L, Gessa GL, FrattaW(1998) Self-Administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience 85:327-330
31. Miliaressis E, Rompre PP (1987) Effects of concomitant motor reactions on the measurement of rewarding efficacy of brain stimulation. Behav Neurosci 101:827-831
32. Miliaressis E, Rompre PP, Laviolette P, Philippe L, Coulombe D (1986) The curve-shift paradigm in selfstimulation. Physiol Behav 37:85-91
33. Onaivi ES, Green MR, Martin BR (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253:1002-1009
34. Panagis G, Vlachou S, Nomikos GG (2008) Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependenceproducing properties. Curr drug Abuse Rev 1:350-374
35. Parker LA, Gillies T (1995) THC-induced place and taste aversions in Lewis and Sprague-Dawley rats. Behav Neurosci 109:71-78
36. Parolaro D, Vigano D, Rubino T (2005) Endocannabinoids and drug dependence. Curr Drug Targets CNS Neurol Disord 4:643-655
37. Patel S, Hillard CJ (2006) Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: Further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318:304-311
38. Polissidis A, Chouliara O, Galanopoulos A, Rentesi G, Dosi M, Hyphantis T, Marselos M, Papadopoulou-Daifoti Z, Nomikos GG, Spyraki C, Tzavara ET, Antoniou K (2010) Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain. Int J Neuropsychopharmacol 13:1175-1191
39. Ramo DE, Liu H, Prochaska JJ (2012) Reliability and validity of young adults' anonymous online reports of marijuana use and thoughts about use. Psychol Addict Behav 26:801-811
40. Robinson L, Hinder L, Pertwee RG, Riedel G (2003) Effects of delta9-THC and WIN-55,212-2 on place preference in the water maze in rats. Psychopharmacology (Berl) 166:40-50
41. Sanudo-Pena MC, Tsou K, Delay ER, Hohman AG, Force M, Walker JM (1997) Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett 223:125-128
42. Sanudo-Pena MC, Romero J, Seale GE, Fernandez-Ruiz JJ, Walker JM (2000) Activational role of cannabinoids on movement. Eur J Pharmacol 391:269-274
43. Smirnov MS, Kiyatkin EA (2008) Behavioral and temperature effects of delta 9-Tetrahydrocannabinol in human-relevant doses in rats. Brain Res 1228:145-160
44. Smith NT (2002) A review of the published literature into cannabis withdrawal symptoms in human users. Addiction 97:621-632
45. Solinas M, Yasar S, Goldberg SR (2007) Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res 56:393-405
46. Takahashi RN, Singer G (1979) Self-Administration of delta 9-Tetrahydrocannabinol by rats. Pharmacol Biochem Behav 11:737-740
47. Tanda G, Pontieri FE, Di Chiara G (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276:2048-2050
48. Tanda G, Munzar P, Goldberg SR (2000) Self-Administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 3:1073-1074
49. Tzavara ET, Wade M, Nomikos GG (2003) Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: Site and mechanism of action. J Neurosci 23:9374-9384
50. Valjent E, Maldonado R (2000) A behavioural model to reveal place preference to delta 9-Tetrahydrocannabinol in mice. Psychopharmacology (Berl) 147:436-438
51. Valjent E, Mitchell JM, Besson MJ, Caboche J, Maldonado R (2002) Behavioural and biochemical evidence for interactions between delta 9-Tetrahydrocannabinol and nicotine. Br J Pharmacol 135:564-578
52. Vlachou S, Markou A (2011) The use of the intracranial self-stimulation in drug abuse research. In: Animal models of drug addiction. Neuromethods, vol. 53 (Olmstead MC, ed), pp3-56. New York: Humana Press and Springer Science
53. Vlachou S, Nomikos GG, Panagis G (2003) WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation. Behav Brain Res 141:215-222
54. Vlachou S, Nomikos GG, Stephens DN, Panagis G (2007) Lack of evidence for appetitive effects of delta 9-Tetrahydrocannabinol in the intracranial self-stimulation and conditioned place preference procedures in rodents. Behav Pharmacol 18:311-319
55. Vlachou S, Stamatopoulou F, Nomikos GG, Panagis G (2008) Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine. Int J Neuropsychopharmacol 11:905-923
56. Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H (2002) Comparison of the subjective effects of delta (9)-Tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berl) 161:331-339
57. Wiley JL, Martin BR (2003) Cannabinoid pharmacological properties common to other centrally acting drugs. Eur J Pharmacol 471:185-193
58. Wise RA (1988) Psychomotor stimulant properties of addictive drugs. Ann N Y Acad Sci 537:228-234
59. Wise RA (1996) Addictive drugs and brain stimulation reward. Annu Rev Neurosci 19:319-340
60. Zangen A, Solinas M, Ikemoto S, Goldberg SR, Wise RA (2006) Two brain sites for cannabinoid reward. J Neurosci 26:4901-4907